Table 1 Account of LncRNAs responsible for blood cells related cancer and malignancies
LncRNA | Disease type | Type of interactions | Molecular functions | References |
|---|---|---|---|---|
AC012065.7 | Chronic lymphocytic leukemia (CLL) | Expression | Hypomethylation of AC012065.7 correlated with poor outcomes in CLL | [119] |
BGLT3 | Chronic myeloid leukemia (CML) | Regulation | BCR-ABL repressed LncRNA-BGL3 expression through c-Myc-dependent DNA methylation. While the ectopic expression of this lncRNA sensitize BCR-ABL transformed cell to apoptosis. | [120] |
CCAT1 | Acute myeloid leukemia (AML) | Expression | The over expression of CCAT1 repressed myeloid cell differentiation by sponging the tumour suppressive miR-155 leads to uncontrolled cell proliferation of human myeloid leukemia cell line HL-60. | [121] |
CCDC26 | AML | Regulation | CCDC26 controls growth of myeloid leukemia cells through regulation of KIT expression indicates knockdown of LncRNA expression along with ISCK03, KIT inhibitor decreased the survival of K562 cell line | [122] |
p15-antisense (p15AS) | Acute lymphoblastic leukemia (ALL) | Expression | Higher expression p15AS levels facilitates the cancer progression in ALL and AML | [123] |
CRNDE | CLL | Expression | CRNDE plays a major role in B cell development, found to be hypermethylation in CLL. | [119] |
DLEU1 | CLL, Myeloma | Mutation, Regulation, Expression, Locus mutation | DLEU2 overexpression blocks cellular proliferation and inhibits the colony-forming ability of tumor cell lines in a miR-15a/miR-16-1-dependent manner. | |
FAS-AS1 | B-cell lymphoma (BCL) | NA | EZH2 is the functional component of PCR2 often over express in lymphomas, involve in hypermethylation of FAS-AS1 promoter and represses the FAS-AS1 expression leads to increased production of sFAS correlates with poor prognosis and chemoresistance. | [60] |
GAS5 | Liver cancer and mantle cell lymphoma | Mutation, Regulation | Down-regulation of GAS5 often detected in melanoma, BCL, and prostate, liver and breast cancer. The expression of GAS5 associated with enhanced secretion of IFNγ in NK cells and also responsible for cytotoxic and cytostatic effects of rapalogues in MCL | |
BM742401 | CLL | Locus | BM742401 is a tumor suppressor lncRNA inactivated by DNA methylation in CLL | [67] |
HOTAIR | Acute leukemia, BCL | Regulation, Expression | HOTAIR may be regarded as a novel indicator of poor prognosis, and may serve as a potential target for gene therapy in the treatment of leukemia and lymphoma. | |
HOTAIRM1 | Leukemia | Expression | HOTAIRM1 is a promising lncRNA biomarker in leukemia and solid tumors. | [136] |
HOXA-AS2 | NB4 promyelocytic leukemia | Regulation | ATRA induces the expression of lincHOXA-AS2 antisense non coding RNA suppress the apoptosis of cancer cell through TNF-related apoptosis-inducing ligand (TRAIL) mediated pathway. | [137] |
HULC | BCL | Expression | HULC could represent a novel indicator of poor prognosis and may be served as a potential target for the diagnosis and gene therapy of diffuse large B-cell lymphoma (DLBCL). | [138] |
LINC-223 | Leukemia | NA | Increased expression of linc-223 arrest the cell cycle progression and contribute to monocytes differentiation in AML cells. | [139] |
Lnc-NKX2-3-1 and Lnc-RTN4R1 | B-cell precursor acute lymphoblastic leukemia | NA | Inhibition of Lnc-RTN4R-1 and lnc-NKX2-3-1 in ETV6/RUNX1 positive cells caused profound changes in gene expression. | [140] |
LOC283177 | DLBCL | NA | The lncRNA LOC283177 had a partial duplication in the C-terminal region and found to be associated with disease risk in DLBCL. | [141] |
LUNAR1 | T-cell acute lymphoblastic leukemia, DLBCL | Regulation | The expression of LUNAR1 is regulated by NOTCH-1, mediates the survival of T-ALL through enhancing IGF1R mRNA expression and sustains IGF1 signaling. The functionality of LUNAR1 also associates with cell proliferation and predicts a poor prognosis in DLBCL. | |
MALAT1 | Multiple myeloma (MM) | Expression | The over expression of MALAT1 was associated with increased pathogenesis of myeloma and it acts as potential indicator of early progression in cancer patients after treatment. | [69] |
MEG3 | Acute and chronic myeloid leukemia, Myelodysplastic syndromes (MDS) and MM | Expression, Epigenetics | The hypermethylation of MEG3 confers worst overall prognosis indicates as potential biomarker and a therapeutic target in leukemia and MM. | |
MIAT | CLL | Regulation | MIAT constitutes a regulatory loop with OCT4 in malignant mature B cell causes uncontrolled proliferation of B cells. | [66] |
MINCR | Burkitt lymphoma (BL) | Regulation | MYC-induced long noncoding RNA (MINCR) had a strong positive correlation with MYC expression and identifying as a crucial player in MYC transcriptional network which able to control the cell cycle genes, | [147] |
LincMONC | Myeloid leukemia | Regulation | LincRNAs MONC and MIR100HG are regulators of hematopoietic lineage decision and promotes the development of myeloid leukemia | [148] |
NALT1 | ALL | Regulation | Lnc-RP11-611D20.2 named NALT1 located near NOTCH1 gene regulate the NOTCH1 mediated signaling pathway through cis- regulation. | [149] |
NEAT1 | Leukemia | Expression | The increased expression NEAT1 facilitates multidrug resistance in leukemia by downregulating the ATP-binding cassette G2 | [150] |
PVT1 | Acute promyelocytic leukemia, BL, Hodgkin’s lymphoma, MM, BCL | Expression, Regulation | The abnormal expression of PVT1 is correlated with uncontrolled proliferation of leukemia and lymphoma. | |
SNHG5 | BCL | Locus | SNHG5 also known as U50HG member of the non-coding multiple snoRNA host gene family, is located at the breakpoint of chromosomal translocation t(3;6)(q27;q15) involved in human BCL. | [158] |
T-ALL-R-LncR1 | ALL | Regulation | T-ALL-R-LncR1 expressed in neoplastic T lymphocytes, knockdown of its expression associated par-4 mediated apoptosis in jurkat cell lines. | [159] |
TCL6 | Leukemia, Lymphoma | NA | Expressed in T-cell leukemia carrying a t(14;14)(q11;q32.1) chromosome translocation indicating a potential role in leukemogenesis. | [160] |
TP73-AS1/ KIAA0495 | MM | NA | Even though methylation of KIAA0495 is high in myeloma cell line, the methylation status inversely correlated with pathogenesis or progression of myeloma. | [161] |
TUSC7 | AML | Expression | Overexpression of the LSAMP and TUSC7 genes in acute myeloid leukemia associated with position effect in an AML patient bearing a 3q13.31 microdeletion | [162] |
UCA1 | AML | Regulation | UCA1 maintains proliferation of AML cells by inhibiting p27kip1cell cycle regulator. | [163] |
WTI-AS | AML | Epigenetics, Interaction | WT-1 is a developmental gene was found mutated in Wilms tumour and AML encodes the WT1-AS acts as important regulator of WT-1 expression. | |
XIST | B-cell acute lymphoblastic leukemia | NA | The expression of XIST plays a crucial role in growth of B-ALL might serve as potential therapeutic target. | [166] |